Immunotherapy & Immuno-Oncology
Part of Healthcare - Oncology
 JNJ | Johnson & Johnson | $0.6t | $255.00 | +0.7% | 3.9M |
 ABBV | ABBVIE INC. | $464.4b | $266.10 | +0.3% | 2.8M |
 MRK | Merck & Co., Inc. | $356.0b | $141.59 | +1.7% | 6.2M |
 AZN | AstraZeneca PLC | $243.3b | $158.59 | +1.3% | 1.8M |
 AMGN | Amgen Inc | $217.9b | $401.95 | -0.1% | 1.4M |
 BMY | Bristol-Myers Squibb Co. | $124.9b | $59.37 | +1.3% | 7.5M |
 MRNA | Moderna, Inc. Common Stock | $75.9b | $188.34 | -7.8% | 17.9M |
 REGN | Regeneron Pharmaceuticals Inc | $75.7b | $734.30 | +1.6% | 411.6K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | $25.5b | $56.43 | -0.4% | 2.0M |
 IBRX | ImmunityBio, Inc. Common Stock | $10.9b | $9.72 | -6.5% | 14.8M |
 ACLX | Arcellx, Inc. Common Stock | $6.7b | $115.06 | -0.0% | 16.1M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | $6.4b | $13.01 | -8.4% | 17.6M |
 CGON | CG Oncology, Inc. Common stock | $6.0b | $63.65 | -7.4% | 532.0K |
 RCUS | Arcus Biosciences, Inc. | $3.1b | $23.37 | -3.2% | 662.0K |
 PGEN | Precigen, Inc. Common Stock | $3.1b | $7.58 | -2.5% | 4.7M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | $2.4b | $11.33 | -2.5% | 3.5M |
 XNCR | Xencor, Inc. | $1.8b | $24.36 | -5.0% | 1.1M |
 SNDX | Syndax Pharmaceuticals, Inc. | $1.6b | $17.37 | -2.6% | 952.5K |
 NKTR | Nektar Therapeutics | $1.5b | $39.86 | -5.4% | 1.7M |
 INBX | Inhibrx Biosciences, Inc. Common Stock | $1.4b | $93.50 | -0.2% | 128.0K |
 OMER | Omeros Corporation | $1.3b | $18.58 | -2.1% | 902.6K |
 REPL | Replimune Group, Inc. | $1.2b | $13.12 | +0.8% | 2.2M |
 BCAX | Bicara Therapeutics Inc. Common Stock | $1.2b | $16.54 | -4.3% | 874.4K |
 IMTX | Immatics N.V. Ordinary Shares | $1.2b | $7.53 | -2.6% | 845.7K |
 JANX | Janux Therapeutics, Inc. Common Stock | $1.0b | $16.80 | +1.6% | 625.5K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $16.40 | +1.4% | 1.8M |
 CRVS | Corvus Pharmaceuticals, Inc. | $0.9b | $10.55 | -1.9% | 1.2M |
 CADL | Candel Therapeutics, Inc. Common Stock | $0.8b | $9.94 | -3.4% | 810.8K |
 AURA | Aura Biosciences, Inc. Common Stock | $0.6b | $6.17 | -0.6% | 520.7K |
 CTMX | CytomX Therapeutics, Inc. | $0.6b | $2.58 | -0.6% | 1.6M |
 CBIO | Crescent Biopharma, Inc. Common Stock | $0.5b | $13.59 | -2.5% | 448.0K |
 AGEN | Agenus Inc. | $377.6m | $7.55 | -14.2% | 1.4M |
 INDP | Indaptus Therapeutics, Inc. Common Stock | $317.1m | $2.56 | +3.2% | 269.6K |
 GLSI | Greenwich LifeSciences, Inc. | $249.2m | $16.04 | -5.4% | 105.2K |
 MGNX | MacroGenics, Inc. | $228.0m | $3.65 | -3.3% | 566.5K |
 CGEN | Compugen Ltd | $218.8m | $2.23 | -3.5% | 261.5K |
 CUE | Cue Biopharma, Inc. | $185.8m | $23.34 | -5.1% | 168.4K |
 CHRS | Coherus Oncology, Inc. Common Stock | $179.2m | $1.04 | -7.6% | 2.8M |
 ALXO | ALX Oncology Holdings Inc. Common Stock | $168.7m | $1.10 | -9.5% | 928.0K |
 CMPX | Compass Therapeutics, Inc. Common Stock | $154.3m | $0.99 | +4.6% | 6.7M |
 HURA | TuHURA Biosciences, Inc. Common Stock | $121.7m | $1.96 | +4.3% | 178.5K |
 GNLX | Genelux Corporation Common Stock | $115.8m | $2.54 | -2.3% | 76.5K |
 ANIX | Anixa Biosciences, Inc. | $102.6m | $3.02 | +2.0% | 337.7K |
 ONCY | Oncolytics Biotech, Inc. Common Shares | $80.5m | $0.60 | +0.5% | 843.0K |
 MAIA | MAIA Biotechnology, Inc. | $73.5m | $1.19 | +1.7% | 224.0K |
 XBIT | XBiotech Inc | $66.8m | $2.17 | -0.2% | 11.6K |
 XLO | Xilio Therapeutics, Inc. Common Stock | $59.3m | $9.03 | -3.0% | 5.6K |
 PDSB | PDS Biotechnology Corporation Common Stock | $54.4m | $1.04 | -12.9% | 16.7M |
 INMB | INmune Bio Inc. Common stock | $53.6m | $1.86 | -3.4% | 305.7K |
 ELTX | Elicio Therapeutics, Inc. Common Stock | $50.5m | $1.88 | -1.6% | 247.7K |